

31 January 2023

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Revised notice of audited results (15 months to 31 August 2022)

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, announces that it is now expecting to release its audited results for the 15 months to 31 August 2022 by the end of February 2023 (the "Audited Results").

As previously announced, Oncimmune has amended its accounting reference date from 31 May to 31 August, in order to reconcile more closely reporting for its ImmunoINSIGHTS service business with the procurement cycles of its clients and through this to provide better alignment between contract awards and revenue recognised during the same financial year. Oncimmune had previously indicated its expectation to release the Audited Results by 31 January 2023.

Recent updates on Oncimmune's trading since 31 May 2022 are contained within other recent announcements by the Company, including those issued on 7 December 2022, in conjunction with its fundraise, and on 20 December 2022, relating to the signing of additional contracts in the ImmunoINSIGHTS business, which help underpin management expectations for the current financial year to 31 August 2023 and give the Board continued confidence in the outlook for the business.

For further information:

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

contact@oncimmune.co.uk

Singer Capital Markets (Nominated Adviser and Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

+44 (0)20 7496 3000

WG Partners (Joint Broker)

David Wilson, Nigel Barnes, Erland Sternby

+44 (0)20 3705 9321

For more information, visit www.oncimmune.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how

RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORDGGDBIXXDGXG